Related Experiment Video
Updated: Feb 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Immune checkpoint inhibitors in renal cell carcinoma
1Department of Oncology, Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, U.K.
Abstract:
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain. Renal cancer was, historically, one of a small number of tumour types where immune manipulation had been shown to be effective. The current generation of immune checkpoint inhibitors are rapidly entering into routine clinical practice in the management of a number of tumour types, including renal cancer, where one drug, nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody (mAb), is licensed for patients who have progressed on prior systemic treatment. Ongoing trials aim to maximize the benefits that can be gained from this new class of drug by exploring optimal timing in the natural course of the disease as well as combinations with other checkpoint inhibitors and drugs from different classes.
Insights
The immune system aids in cancer defense, with immune checkpoint inhibitors like nivolumab showing promise for renal cancer treatment. Research is ongoing to optimize these therapies for better patient outcomes.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- The immune system's role in cancer defense is well-established, with historical success in immune manipulation for renal cancer.
- Immune checkpoint inhibitors represent a significant advancement in cancer therapy.
Discussion:
- Nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody (mAb), is approved for advanced renal cancer post-systemic treatment.
- This highlights the growing clinical application of immune checkpoint inhibitors in oncology.
Key Insights:
- Renal cancer has historically responded to immune manipulation strategies.
- Current research focuses on optimizing PD-1 inhibitor therapy timing and combinations.
Outlook:
- Ongoing clinical trials explore maximizing benefits from PD-1 inhibitors through combination therapies and strategic timing.
- Further research aims to integrate these novel immunotherapies into standard renal cancer care.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Antihypertensive Drugs: Direct Renin Inhibitors
Acute Kidney Injury IV: Diagnostic Studies and Prevention

